Evidence map›Paper›PMID 32959885›Full record

ArticleHistology and histopathology2020

Proliferative and chondrogenic potential of mesenchymal stromal cells from pluripotent and bone marrow cells.

Irene Sfougataki, Ioanna Varela, Kalliope Stefanaki, Angeliki Karagiannidou, Maria G Roubelakis, Vasiliki Kalodimou, Ioanna Papathanasiou, Joanne Traeger-Synodinos, Sofia Kitsiou-Tzeli, Emmanuel Kanavakis and 4 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. PSC-MSC-Derived Exosomes Protect against Kidney FibrosisInternational journal of stem cells · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Irene SfougatakiStem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Ioanna VarelaStem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Kalliope StefanakiDepartment of Histopathology, Aghia Sophia Children's Hospital, Athens, Greece.
Angeliki KaragiannidouStem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Maria G RoubelakisLaboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Vasiliki KalodimouFlow Cytometry-Research and Regenerative Medicine Department, IASO Hospital, Athens, Greece.
Ioanna PapathanasiouLaboratory of Cytogenetics and Molecular Genetics, Faculty of Medicine, University of Thessally, Thessally, Greece.
Joanne Traeger-SynodinosDepartment of Medical Genetics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Sofia Kitsiou-TzeliDepartment of Medical Genetics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Emmanuel KanavakisGenesis Genoma Lab, Genetic diagnosis, Clinical Genetics and Research, Chalandri, Greece.
Vasiliki KitraStem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Aspasia TsezouLaboratory of Cytogenetics and Molecular Genetics, Faculty of Medicine, University of Thessally, Thessally, Greece.
Maria TzetisDepartment of Medical Genetics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Evgenios GoussetisStem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Children's Hospital Agia Sophia · GRNational and Kapodistrian University of Athens · GR

Funding

- -
6 · The paper itself

Abstract

introductionMesenchymal stromal cells (MSCs) can be derived from a wide range of fetal and adult sources including pluripotent stem cells (PSCs). The properties of PSC-derived MSCs need to be fully characterized, in order to evaluate the feasibility of their use in clinical applications. PSC-MSC proliferation and differentiation potential in comparison with bone marrow (BM)-MSCs is still under investigation. The objective of this study was to determine the proliferative and chondrogenic capabilities of both human induced pluripotent stem cell (hiPSC-) and embryonic stem cell (hESC-) derived MSCs, by comparing them with BM-MSCs.

methodsMSCs were derived from two hiPSC lines (hiPSC-MSCs), the well characterized Hues9 hESC line (hESC-MSCs) and BM from two healthy donors (BM-MSCs). Proliferation potential was investigated using appropriate culture conditions, with serial passaging, until cells entered into senescence. Differentiation potential to cartilage was examined after in vitro chondrogenic culture conditions.

resultsBM-MSCs revealed a fold expansion of 1.18x10⁵ and 2.3x10⁵ while the two hiPSC-MSC lines and hESC-MSC showed 5.88x10¹⁰, 3.49x10⁸ and 2.88x10⁸, respectively. Under chondrogenic conditions, all MSC lines showed a degree of chondrogenesis. However, when we examined the formed chondrocyte micromasses by histological analysis of the cartilage morphology and immunohistochemistry for the chondrocyte specific markers Sox9 and Collagen II, we observed that PSC-derived MSC lines had formed pink rather than hyaline cartilage, in contrast to BM-MSCs.

conclusionIn conclusion, MSCs derived from both hESCs and hiPSCs had superior proliferative capacity compared to BM-MSCs, but they were inefficient in their ability to form hyaline cartilage.

Indexed as

Cell DifferentiationCell ProliferationChondrogenesisAnimalsBiomarkersBone Marrow CellsCell LineCollagen Type IIHuman Embryonic Stem CellsHumansInduced Pluripotent Stem CellsMesenchymal Stem CellsMice, Inbred NODMice, SCIDPhenotypeSignal TransductionBiomarkersCollagen Type IISOX9 protein, humanSOX9 Transcription Factor

Identifiers

PMID32959885
OpenAlexW3087542263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.